PMID- 8822126
OWN - NLM
STAT- MEDLINE
DCOM- 19961119
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 81
IP  - 2 Suppl
DP  - 1996
TI  - Patients at risk of venous thromboembolism--clinical results with reviparin.
PG  - S39-45
AB  - Perioperative thromboembolism can be effectively prevented by low-dose heparin. 
      However, its clinical benefit is limited, due to the risk of bleeding, the need 
      for multiple daily doses, infrequent disorders of platelet function and other 
      potential side effects. Low molecular weight heparin (LMWH) was developed with 
      the aim that the antithrombotic efficacy of heparin could be maintained, while 
      the risk of bleeding and other side effects would be reduced. Prior to recent 
      studies, the anticipated clinical benefit of LMWH remained a controversial issue. 
      We have reviewed the clinical pharmacology and the results of several prospective 
      trials using reviparin a LMWH which has been compared with unfractionated heparin 
      (UFH) and another LMWH. The efficacy and safety of reviparin was examined in the 
      prevention of venous thromboembolism in high risk patients undergoing elective 
      major abdominal and hip surgery. The results of these clinical trials show that 
      reviparin is as effective as UFH in preventing venous thromboembolism whilst 
      having a lower incidence of bleeding complications. Of major significance was the 
      finding that a very low dose of reviparin, namely 1750 anti-Xa IU once daily, was 
      found to be as effective as UFH in preventing deep vein thrombosis whilst having 
      a significantly lower incidence of bleeding complications in patients undergoing 
      major abdominal surgery. Reviparin has also been shown to be effective and safe 
      as enoxaprin in patients undergoing elective hip surgery. Further clinical trials 
      are required to test different dosage regimens as a thromboprophylactic agent in 
      high risk patients. It is possible that reviparin and other LMWHs with similar 
      pharmacological properties may have an important clinical benefit over earlier 
      compounds. However, this needs to be assessed in large scale, double-blind, 
      randomised clinical trials.
FAU - Kakkar, V V
AU  - Kakkar VV
AD  - Thrombosis Research Institute, London, UK.
FAU - Cohen, A T
AU  - Cohen AT
FAU - Mohamed, M S
AU  - Mohamed MS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5R0L1D739E (reviparin)
SB  - IM
MH  - Abdomen/surgery
MH  - Anticoagulants/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Hip/surgery
MH  - Humans
MH  - Postoperative Complications/etiology/prevention & control
MH  - Risk Factors
MH  - Thrombophlebitis/etiology/*prevention & control
RF  - 11
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1016/0049-3848(95)00228-6 [doi]
PST - ppublish
SO  - Thromb Res. 1996;81(2 Suppl):S39-45. doi: 10.1016/0049-3848(95)00228-6.